Methods of using insulin in combination with blood glucose-lowering drugs

People with diabetes often have problems with insulin or glucose. So, if the combination of insulin and glucose-lowering drugs, what will be the impact? This article will provide more information to help patients better understand when combining insulin and blood glucose lowering drugs.

Insulin is a substance capable of stabilizing blood sugar for the body. Patients diagnosed with diabetes will have problems with their blood sugar due to poorly functioning insulin. However, when using injectable insulin, it can cause the body to lower blood sugar.
These clinical results make both doctors and patients apprehensive about insulin therapy. The predicted problems can be weight gain, low blood sugar, health and mental deterioration. Part of the cause may come from the patient's family or psychology. Therefore, it is necessary to have a reasonable treatment regimen to achieve maximum effectiveness.
Fears that insulin injections cause hypoglycemia have become the subject of scientific research. When used in combination with insulin and hypoglycemic drugs can increase the effectiveness of treatment. So where does the cause come from?

To check the safety level, the doctors conducted analysis in many subjects and the results from the sample were extremely diverse. Especially in type 2 diabetes, metformin combined with insulin will address the physiological mechanism of the disease. In some cases, an appropriate reduction in the insulin dose will be considered and at the same time an improvement in the received treatment effect.
When using this therapeutic mechanism, DPP4i will be coadministered to reduce insulin secretion from the cells. At the same time, glucose will be produced in the liver, but metformin will improve the resistance of the liver. Therefore, the amount of glucose produced in the liver is also inhibited and secreted.
Another study used vildagliptin in combination with insulin. This is a placebo using about 100 mg/day. That combination will limit the body's hypoglycemia compared to when insulin alone. The effectiveness of this treatment is believed to be highly effective in the Asian population. During the course of treatment, the number of patients who died due to hypoglycemia also decreased gradually.
Expanding the study with insulin plus placebo, doctors selected patients with type 2 diabetes with moderate to severe renal failure. Severely ill patients will be adjusted to a 0.6 percent reduction of placebo in the treatment area compared to the average. Post-treatment results are quite complex.
Finally, the effect shows that the therapy can limit hypoglycaemia. According to the analysis, patients on long-term treatment with placebo and insulin may experience increased efficacy and safety. However, the dose should always be carefully adjusted to best suit the patient's health condition.
Results are considered accurate when following treatment from 2 years. The vildagliptin group was able to reduce their insulin dose. However, there will be side effects during treatment, but they are usually not serious and have not been recorded as dangerous for patients.
Type 2 diabetes is a factor that doubles your risk of cardiovascular disease. If not treated early, the disease will spread, destroy the entire body's immune system, even lead to death.
Using combination therapy with insulin with hypoglycaemic agents will be able to control the lowest dose of insulin. At the same time, patients reduce the risk of death due to hypoglycemia. At the same time, the effect is also safe in patients with renal failure. If you need more information, you can consult a specialist.